Suppr超能文献

动脉高血压治疗中治疗效果及风险的年龄依赖性?

Age dependence of therapy result and risk in the treatment of arterial hypertension?

作者信息

Höffler D, Morgenstern H O

机构信息

Medizinische Klinik III, Städtische Krankenanstalten, Darmstadt, FRG.

出版信息

J Cardiovasc Pharmacol. 1990;16 Suppl 5:S184-8.

Abstract

In an open multicenter study, 2,012 patients with mild to moderate essential hypertension were treated for 8 weeks with the beta1-selective blocker bisoprolol. A total of 570 general practitioners participated in this study. A total of 1,597 patients whose resting diastolic blood pressure (DBP) ranged from 95 to 115 mm Hg were considered eligible for this study. Patients received one tablet of bisoprolol (5 mg) o.d. for the first 4 weeks. In patients not responding satisfactorily to treatment, the dose could be increased to 10 mg o.d. for the following 4 weeks. A total of 1,201 patients were evaluated for efficacy and all 2,012 patients were evaluated for tolerability. After 4 weeks of therapy, mean systolic blood pressure (SBP) was lowered significantly from 170+/-15 to 151+/-14 mm Hg, and mean DBP was lowered from 104+/-5 to 92+/-7 mm Hg. A further 4-week treatment lowered the blood pressure even more: mean SBP from 151+/-14 to 144+/-13 mm Hg and mean DBP from 92+/-7 to 88+/-7 mm Hg. The total extent of both SBP and DBP reduction was equal in all age groups and showed no dependency of the initial blood pressure value. At the end of the study. the responder rate was 94.9% in patients aged under 60 years, and 90.6% in patients aged over 60 years. The age group 31-40 years showed the highest responder rate (97.5%). After 8 weeks of treatment, 69.5% of the patients were still on 5 mg of bisoprolol and 27.6% on 10 mg of bisoprolol. Of all 2,012 patients, 11.6% reported side effects such as vertigo, fatigue. gastrointestinal disturbances, and headache. The incidence of adverse drug reactions was highest in the age group 31-40 years. Bisoprolol proved in this study to be an effective and safe antihypertensive agent when given to patients with mild to moderate hypertension for 8 weeks.

摘要

在一项开放性多中心研究中,2012例轻至中度原发性高血压患者接受β1选择性阻滞剂比索洛尔治疗8周。共有570名全科医生参与了这项研究。共有1597例静息舒张压(DBP)在95至115mmHg之间的患者被认为符合本研究条件。患者在最初4周每天服用一片比索洛尔(5mg)。对治疗反应不令人满意的患者,在接下来的4周剂量可增加至每天10mg。共有1201例患者接受了疗效评估,所有2012例患者均接受了耐受性评估。治疗4周后,平均收缩压(SBP)从170±15显著降至151±14mmHg,平均DBP从104±5降至92±7mmHg。再治疗4周后血压进一步降低:平均SBP从151±14降至144±13mmHg,平均DBP从92±7降至88±7mmHg。SBP和DBP降低的总体程度在所有年龄组中相同,且与初始血压值无关。在研究结束时,60岁以下患者的有效率为94.9%,60岁以上患者为90.6%。31 - 40岁年龄组的有效率最高(97.5%)。治疗8周后,69.5%的患者仍服用5mg比索洛尔,27.6%的患者服用10mg比索洛尔。在所有2012例患者中,11.6%报告有眩晕、疲劳、胃肠道不适和头痛等副作用。药物不良反应发生率在31 - 40岁年龄组最高。在本研究中,比索洛尔用于轻至中度高血压患者8周时,被证明是一种有效且安全的抗高血压药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验